Cefpirome
- CAS NO.:84957-29-9
- Empirical Formula: C22H22N6O5S2
- Molecular Weight: 514.58
- MDL number: MFCD00864933
- EINECS: 1592732-453-0
- SAFETY DATA SHEET (SDS)
- Update Date: 2023-05-04 17:34:43
What is Cefpirome?
Description
This drug is resistant with respect to a broad spectrum of beta-lactamases. Its spectrum of activity is analogous to that of the third-generation cephalosporin cefotaxime (32.1.2.56), although it is more active with respect to some staphylococci, enterococci, and also a few enterobacteria. Synonyms of this drug are cefrom, cedixen, and others.
The Uses of Cefpirome
Cephalosporin antibiotic Claforan
Definition
ChEBI: Cefpirome is a fourth-generation cephalosporin antibiotic having 6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively. It is a cyclopentapyridine and a cephalosporin.
brand name
Cefrom (Hoechst-Roussel).
Antimicrobial activity
A semisynthetic aminothiazoyl cephalosporin formulated as
the sulfate for parenteral administration. Activity against common
pathogens is similar to that of cefotaxime
and ceftriaxone, but it is more active against Ps. aeruginosa.
Unlike other cephalosporins it exhibits activity against some
strains of enterococci (MIC 4–16 mg/L), but this is of doubtful
clinical benefit. It is generally very stable to β-lactamases.
It is active against strains of Enterobacter spp., Citrobacter spp.,
Hafnia spp., Providencia spp., Ser. marcescens and Pr. vulgaris
producing molecular class C cephalosporinases.
Sten. maltophilia is resistant.
A 1 g intramuscular injection produces a plasma concentration
of 25 mg/L after 1.6–2.3 h. A similar intravenous
dose achieves a peak concentration of 97 mg/L. The plasma
half-
life is 1.4–2.3 h and protein binding is around 10%. It
is well distributed, achieving therapeutic concentrations in
tissues and exudates. It penetrates poorly into CSF in the
absence of meningeal inflammation, but concentrations
around 2–4 mg/L have been found in patients with purulent
meningitis.
Little, if any, of the drug is metabolized and most is excreted
unchanged in the urine within 12 h, mainly by glomerular filtration.
Clearance declines in proportion to renal function.
Around 60% of the drug is removed in 3 h by hemodialysis.
Low concentrations are found in breast milk.
Side effects are those common to other cephalosporins.
Diarrhea is common and occasional cases of pseudomembranous
colitis have been reported.
It is mainly used in the treatment of serious sepsis, particularly
nosocomial infections in which resistant Gram-negative
pathogens are known or suspected to be involved. It is not
widely available, but is marketed in Japan.
Clinical Use
Cefpirome (Cefrom) is a newer parenteral, -lactamase–resistant cephalosporin with a quaternary ammonium groupat the 3-position of the cephem nucleus. Because its potencyagainst Gram-positive and Gram-negative bacteria rivals thatof the first-generation and third-generation cephalosporins,respectively, cefpirome is being touted as the first fourthgenerationcephalosporin. Its broad spectrum includesmethicillin-sensitive staphylococci, penicillin-resistantpneumococci, and β-lactamase–producing strains of E. coli,Enterobacter, Citrobacter, and Serratia spp. Its efficacyagainst P. aeruginosa is comparable with that of ceftazidime.Cefpirome is excreted largely unchanged in the urine with ahalf-life of 2 hours.
Synthesis
Cefpirome, {6R-[6α,7β(Z)]}-1-[(7-{[(2-amino-4-thiazolyl)-(methoximino) acetyl]amino}-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl- 1-methyl]pyrrolidine chloride (32.1.2.100), is also synthesized by methods described for synthesizing third-generation cephalosporins, in particular, ceftazidime (32.1.2.82).
Metabolism
Not Available
Properties of Cefpirome
storage temp. | 2-8°C(protect from light) |
Safety information for Cefpirome
Signal word | Warning |
Pictogram(s) |
Exclamation Mark Irritant GHS07 |
GHS Hazard Statements |
H302:Acute toxicity,oral H315:Skin corrosion/irritation H319:Serious eye damage/eye irritation H335:Specific target organ toxicity, single exposure;Respiratory tract irritation |
Precautionary Statement Codes |
P261:Avoid breathing dust/fume/gas/mist/vapours/spray. P301+P312:IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. P302+P352:IF ON SKIN: wash with plenty of soap and water. P304+P340:IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing. |
Computed Descriptors for Cefpirome
New Products
4-AMINO-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HCL 4-(Dimethylamino)tetrahydro-2H-pyran-4-carbonitrile 4-Aminotetrahydropyran-4-carbonitrile Hydrochloride (R)-3-Aminobutanenitrile Hydrochloride 3-((Dimethylamino)methyl)-5-methylhexan-2-one oxalate 1,4-Dioxa-8-azaspiro[4.5]decane 5-Bromo-2-nitropyridine Nimesulide BP Aceclofenac IP/BP/EP Diclofenac Sodium IP/BP/EP/USP Mefenamic Acid IP/BP/EP/USP Ornidazole IP Diclofenac Potassium THOMAIND PAPER PH 2.0 TO 4.5 1 BOX BUFFER CAPSULE PH 9.2 - 10 CAP SODIUM CHLORIDE 0.1N CVS ALLOXAN MONOHYDRATE 98% PLATINUM 0.5% ON 3 MM ALUMINA PELLETS (TYPE 73) LITHIUM AAS SOLUTION 2-Bromo-1-(bromomethyl)-3-chloro-5-nitrobenzene 2-Bromo-3-nitroaniline N-(3-Hydroxypropyl)-N-methylacetamide 3-Bromo-6-chloropyridazine 4-ethyl-3-nitrobenzoic acidRelated products of tetrahydrofuran
You may like
-
1-Methyl-6-oxo-1,6-dihydropyridazine-3-carbonitrile 98%View Details
99903-60-3 -
88491-46-7 98%View Details
88491-46-7 -
1823368-42-8 98%View Details
1823368-42-8 -
2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%View Details
1307449-08-6 -
Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%View Details
25408-95-1 -
2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%View Details
1805639-70-6 -
1784294-80-9 98%View Details
1784294-80-9 -
Lithium ClavulanateView Details
61177-44-4